论文部分内容阅读
目的:通过检测MHC-Ⅰ类分子链相关蛋白A/B(MHC classⅠchain-related protein A/B,MICA/B)在HER2阳性乳腺癌组织中的表达水平,探讨其与患者临床病理特征的关系。方法:收集2009年1月至2010年6月在南方医科大学附属郑州人民医院乳腺外科手术切除的HER2阳性乳腺癌标本62例及其临床资料,免疫组化法检测乳腺癌组织中MICA/B的表达水平,分析其与患者临床病理特征的关系。结果:MICA/B表达率为90.32%,高表达为64.52%。MICA/B的表达与患者的临床分期、ER、PR表达有关(均P<0.05),与绝经、淋巴结转移、组织学分级无关(均P>0.05)。结论:MICA/B的表达可能与HER2阳性乳腺癌的发生发展有关,有望成为免疫治疗的新靶点。
OBJECTIVE: To investigate the relationship between the expression of MHC class Ⅰ chain-related protein A / B (MICA / B) and the clinicopathological features of HER2 positive breast cancer by detecting the expression level of MHC class Ⅰ chain-related protein A / B (MICA / B) Methods: 62 cases of HER2-positive breast cancer resected by breast surgery in Zhengzhou People’s Hospital Affiliated to Southern Medical University from January 2009 to June 2010 were collected, and their clinical data were collected. The expression of MICA / B in breast cancer tissues was detected by immunohistochemistry Expression level, analyze its relationship with the clinicopathological features of patients. Results: MICA / B expression rate was 90.32%, high expression was 64.52%. The expression of MICA / B was correlated with clinical stage, ER, PR expression (all P <0.05), but not with menopause, lymph node metastasis and histological grade (all P> 0.05). Conclusion: The expression of MICA / B may be related to the occurrence and development of HER2 positive breast cancer, which may be a new target of immunotherapy.